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Treatment wish of individuals with known 
and unknown restless legs syndrome in the 
community
Introduction
In 1995, the International Restless Legs Syndrome Study 
Group (IRLSSG) published diagnostic criteria for the 
restless legs syndrome (RLS) [11], the so-called minimal 
criteria. These criteria and their little revision in 2003 [1] 
formed the basis for a wider assessment of RLS in popu-
lation studies in subsequent years. Since then many 
studies assessing the prevalence of restless legs syn-
drome in the general population or specific patient pop-
ulations have been published, especially in this century 
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■ Abstract  Study objectives Rest-
less legs syndrome (RLS) is a fre-
quent sleep disorder with a preva-
lence of 5 % to 15 % in Caucasion 
populations. Dopaminergic treat-
ment is known to reduce sensori-
motor RLS symptoms and is ap-
proved for RLS, but not all patients 
ask for treatment. About 2 % to 3 % 
of patients presenting to a primary 
care physician require RLS-specific 
treatment. The overall treatment 
preference of RLS sufferers, how-
ever, is still unknown. The aim of 
this study was to assess the preva-
lence and treatment preference in 
patients with previously diagnosed 
and those with yet undiagnosed 
RLS in a population-based survey 
in Germany. Design and setting 
Cross-sectional health survey with 
face-to-face interviews with 1312 
participants in the Dortmund 
Health Study. RLS was assessed 
with standardized, validated ques-
tions addressing the four minimal 
diagnostic criteria for RLS defined 
by the International Restless Legs 
Syndrome Study Group. Partici-
pants Participants were aged 25 to 
75 years and were randomly se-
lected from the city register. Results 
The overall prevalence of individu-
als with a known doctor diagnosis 
of RLS was 2.3 %. In addition, 6.5 % 
fulfilled the four minimal criteria 
but did not know about this diag-
nosis yielding an overall prevalence 
of 8.8 %. Prevalence was higher in 
women (10.2 %) and German de-
scendents (9.2 %) compared to men 
(7.1 %) and migrants (6.7 %). Al-
most 60 % of all RLS cases reported 
symptoms at least once a week. 
33.3 % of cases with a known RLS 
diagnosis and 14.1 % with an un-
known diagnosis had an RLS treat-
ment wish. The latter is determined 
by knowledge of the diagnosis, 
daily symptoms, diabetes and sleep 
disturbance. Conclusion About 
 every fourth RLS case knows about 
the diagnosis and overall every 
fifth RLS case wishes medication to 
effectively reduce symptoms, 
 corresponding to 1.6 % of the 
whole study population. 
■ Key words  restless legs 
 syndrome (RLS) · prevalence · 
treatment wish
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(for review see [5]). The vast majority of the studies that 
applied the four diagnostic criteria stated in their intro-
duction or discussion that RLS is either underdiagnosed 
or still not well-known in the medical community. How-
ever, 12 years after the publication of the diagnostic 
 criteria and 322 years after its first description by Sir 
Thomas Willis (in the year 1685) [12], the question arises 
if RLS still represents “the most common unknown dis-
ease you have never heard of” [13]. There are doubts 
about this especially since the past decade has seen a 
strong increase in the interest in the disease with the 
registration of effective drugs for treatment of RLS, the 
establishment of patient support groups in many coun-
tries worldwide and the development of tools to assess 
severity, disease-specific quality of life and other aspects 
of RLS.
The availability of registered drugs for treating RLS 
symptoms has brought up in more detail the question 
when drug treatment of RLS should be started. There is 
no absolute indication or need to treat RLS. It is the pa-
tient whose symptom severity determines the treatment 
decision. It is unknown to date how many RLS cases 
 actually wish treatment with medication, given the con-
siderable costs of registered drugs, such as dopamine 
agonists. Knowing this proportion would enable the es-
timation of treatment needs and of costs of treatment in 
a specific population or specific region such as Ger-
many. 
Our study had two aims, first to assess the proportion 
of individuals who have a medical diagnosis of RLS and, 
thus, know about the disease, in comparison to the pro-
portion of subjects fulfilling the minimal criteria but 
have not had a RLS diagnosis. Second, to assess the wish 
for treatment in affected cases and to analyse determi-
nants influencing this wish.
Patients and methods
■ Subjects
The Dortmund Health Study (DHS) is a population-based health sur-
vey conducted in the city of Dortmund in the west of Germany. Pri-
mary aim of this study is to determine the prevalence of cardiovascu-
lar and other chronic diseases, headache types and behavior dependent 
risk factors in this population. Participation was restricted to age 
groups 25 to 75 years. From the total population of 587,607 living in 
Dortmund on December 31, 2003, a random sample of 3820 persons 
was drawn from the population register, independent of nationality 
and stratified by 5-year age groups and gender. From these, 395 per-
sons were non-eligible because of death, or having moved outside the 
study area between sampling and invitation, or lack of sufficient 
knowledge of the German language to understand informed consent. 
The remaining were invited to an interview and standardized exami-
nation in the central study center located in the city’s Office of Health 
(first choice) or, alternatively (second choice), to answer a standard-
ized questionnaire with a reduced but otherwise identical set of ques-
tions. Overall, 1312 individuals participated in the personal interview 
and 979 completed the questionnaire. The overall response propor-
tion was 67 %, the proportion with a personal interview was 38.3 % of 
all eligibles, and 57.3 % of all participants. Traditionally, many people 
with a migration background particularly from Eastern Europe, Italy, 
Spain, and Turkey live in Dortmund in the first, second or third gen-
eration. In 2003, 12.9 % of the inhabitants had a foreign nationality.
 RLS assessment was restricted to interview participants only, be-
cause the respective questions were not included in the questionnaire 
due to the reduced space available. RLS assessment was done in face-
to-face interviews with a short questionnaire that had been previ-
ously validated against physician classification [3] and had already 
been used in identical form in two other German studies [2, 9]. In 
brief, the following questions were used according to the minimal cri-
teria published by the International Restless Legs Syndrome Study 
Group [1]: 1) Do you have sensory discomfort like tingling, crawling 
with ants or pain in the legs associated with an urge to move? 2) Do 
these symptoms occur at rest, i.e., while sitting down or falling asleep, 
and do they improve by moving? 3) Are these symptoms worse in the 
evening or at night, compared with the morning? The three answer 
categories included “Yes”, “No” or “Don’t know”. Participants were 
only classified as RLS positive if they answered all three questions 
with “Yes”. Knowledge of an RLS diagnosis was assumed if a partici-
pant answered “Yes” to the question if he or she was ever diagnosed 
with RLS by a physician. Socio-demographic data, medical histories 
including neurological diseases, other comorbidities and several 
health-related lifestyle variables were also assessed in interview form 
by trained and certified interviewers. The current medication, taken 
within the last seven days, was listed and subsequently classified ac-
cording to the Anatomical –Therapeutical Classification (ATC Code). 
For this analysis, the following medication codes were considered: 
levodopa (N04BA), dopamine agonists (N04BC), anticonvulsants 
(N03A), opioids (N02A), and benzodiazepines (N03AE, N05BA, 
N05CD, N05CF). Treatment wish was assessed by a single question 
(“Are your symptoms so severe that you would consider taking a 
medication if this would effectively reduce them?”). Answer options 
were “Yes”, “No” and “Don’t know”. A “Yes” answer was assumed to 
express treatment wish.. Height, weight and blood pressure were mea-
sured using standard protocols. Seven questions of the Pittsburgh 
Sleep Quality Index (PSQI) [4], enabling the calculation of compo-
nents 1 (subjective sleep quality), 3 (sleep duration), 4 (sleep effi-
ciency), and 7 (day sleepiness) were used to assess sleep problems. 
Migrational background was classified based on nationality (pass-
port) and four additional questions asking for own place of birth and 
the nationality of mother and father. Written informed consent was 
obtained from all participants in the interview and the study protocol 
was approved by the local ethics committee of the Medical Faculty at 
the University of Münster.
■ Statistical analysis
Differences in categorical variables between the two groups with a 
known and unknown RLS diagnosis were compared using Chi-square 
test or Fisher’s exact test (if a cell number was 5 or less). Differences 
in means or medians of continuous variables were compared using 
Student’s t-test (means) or the Wilcoxon rank sum test (medians), 
respectively. Multivariable logistic regression was used to analyse de-
terminants of treatment wish for RLS with this wish being the di-
chotomous (yes – no) dependent variable. All analyses were done in 
Stata (version 6.0). 
Results 
■ Demographics of the study population
In the Dortmund Health Study (DHS), 1312 participants 
(52.9 % female) were interviewed by trained interview-
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ers. Of these participants 16.0 % had a migrational back-
ground, 7.3 % reported alcohol consumption of ≥ 40 g/d, 
and 25.5 % were current smokers. Clinical and demo-
graphic data of the study population as well as comor-
bidities such as cardiovascular risk factors are presented 
in Table 1, stratified by RLS status.
■ Prevalence of RLS 
In Table 2, the prevalences of RLS, according to knowl-
edge of a diagnosis, are shown. The prevalence of RLS 
was calculated as (a) RLS previously diagnosed by a phy-
sician independent from fulfillment of the minimal cri-
teria (women: 2.2 %, men: 2.4 %, migrants: 1.9 %, total: 
2.3 %), (b) individuals not knowing about an RLS diag-
nosis but fulfilling the minimal criteria (women: 8.1 %, 
men: 4.7 %, migrants: 4.9 %, total: 6.5 %), (c) all RLS in-
dividuals either fulfilling the minimal criteria or having 
a physician diagnosis of RLS or both (women: 10.2 %, 
men: 7.1 %, migrants: 6.7 %, total: 8.8 %). The overall 
prevalence increased considerably with age in both gen-
ders. Interestingly, the prevalence of a doctor diagnosis 
of RLS was higher in men than in women, while the 
prevalence of unknown RLS was twice as high in women 
as in men. Study participants with a migrational back-
ground had lower prevalences of a known diagnosis of 
RLS as well as an unknown RLS. From the overall 115 
RLS cases, 96 (7.3 %) fulfilled the minimal criteria and 
yielded the prevalence that is directly comparable to the 
other two studies in Germany conducted using identical 
methods. Among the 30 individuals with a known RLS 
diagnosis 21 fulfilled at least one and 11 all of the diag-
nostic minimal criteria at the time of assessment. 
■ Symptom characteristics 
Previously diagnosed RLS patients reported non-sig-
nificantly higher symptom frequency compared to pre-
 Characteristic No RLS












  Age, Mean (years) 51.8 59.4 54.4 0.07
  Women, % 52.1 50.0 65.9 0.12
  School education ≤ 9 years, % 48.7 63.3 56.5 0.51
  Number of children born1, Mean (Median)  1.6 (1)  2.3 (2)  1.4 (2) (0.15)
  Migrational background2, % 16.4 13.3 11.8 0.82
 Risk factors
  BMI ≥ 30, % 25.8 36.7 31.8 0.62
  Alcohol consumption: nondrinker, % 40.1 43.3 41.2 0.51
    1–39 g/d, % 52.6 46.7 54.1
    ≥ 40 g/d, %  7.3 10.0  4.7
  Smoker:
    never, % 44.2 36.7 45.8 0.25
    ex, % 30.3 43.3 27.1
    current, % 25.5 20.0 27.1
 Comorbidities
  History of heart attack3, %  3.7 10.0  2.4 0.08
  Known diabetes3, %  7.5 23.3  7.1 0.02
  Known hypertension3, % 34.6 56.7 36.5 0.05
  Measured hypertension4, % 52.7 63.3 62.4 0.92
  Depressive symptoms5, % 16.3 20.0 22.4 0.79
  History of commotio3, %  6.0  3.3  9.4 0.29
  History of skull fracture3, %  1.0  3.3  0.0 0.26
  History of seizure3, %  1.6  6.7  1.2 0.17
  History of cancer3, %  4.2 13.3  7.1 0.30
  Hysterectomy1, % 22.5 26.7 33.9 0.59
1 Restricted to women only (n = 694)
2 First and second generation migrants, classified by own and parents place of birth and nationality
3 Self-reported physician diagnosis 
4 Systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, mean of two measurements 
10 minutes apart using a standardized measurement protocol
5 Center of Epidemiological Studies Depression Scale score ≥ 16 points (Scale minimum = 0, maximum = 60)
Table 1  Characteristics of the participants in the 
Dortmund Health Study, stratified according to RLS 
status and a known or unknown RLS diagnosis
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viously undiagnosed patients (Table 3). Age of onset was 
significantly higher in previously diagnosed patients 
than in undiagnosed patients (p < 0.01). The latter re-
ported more often a positive family history and slightly 
longer mean symptom duration. However, both results 
were not significantly different in both groups. 13.3 % of 
previously diagnosed RLS patients were on levodopa or 
dopamine agonist treatment, 3.3 % took anticonvulsants. 
Among previously undiagnosed patients only one indi-
vidual received medication with anticonvulsants (1.2 %). 
None of the cases took anticonvulsants for RLS but for 
epilepsy or pain syndromes. No RLS case reported opi-
oid or benzodiazepine intake. Sleep characteristics in 
both RLS groups were considerably worse than those of 
non-affected study participants. In the latter group, 
19.9 % reported poor sleep quality, 17.5 % a sleep dura-
tion < 6 hours, 20.5 % a sleep efficiency < 75 % and 16.5 % 
problems with daytime sleepiness. RLS-unaffected par-
ticipants had a medium sleep summary score of 3. Com-
pared to this unaffected group sleep scores in both RLS 
groups were worse but did not differ significantly be-
Table 2  Prevalence of study participants with RLS according to an individually 
known or unknown diagnosis, stratified by gender, age and migrational back-
ground




N % N % N %
 Total 30 2.3 85 6.5 115  8.8
 Gender
  Women 25–44  2 0.8 19 7.8  21  8.6
45–75 13 2.9 37 8.2  50 11.1
All 15 2.2 56 8.1  71 10.2
  Men 25–44  2 1.1  5 2.8   7  3.9
45–75 13 3.0 24 5.5  37  8.5
All 15 2.4 29 4.7  44  7.1
 Migrational background1
  Yes 25–75  4 1.9 10 4.9  14  6.7
  No 25–75 26 2.4 75 7.0 101  9.2
1 First and second generation migrants, classified by own and parents place of birth 
and nationality












 Symptom frequency 0.18
  daily, % 21.1 14.3 15.5
  3–6 per week, % 36.8 14.3 18.5
  1–2 per week, % 15.8 27.4 25.2
  1–3 per month, % 15.8 28.2 26.2
  ≤ 1 per month, % 10.5 15.5 14.6
 Age of onset (years), Mean 55.6 47.2 49.4 0.01
 Positive family history1, % 14.3 30.6 27.4 0.11
 Symptom duration
  Median, (years)  2.5  3.0  3.0 0.10
 Drug intake2
  L-dopa or dopamine agonists % 13.3  0.0  3.5 0.004
  Anticonvulsants, %  3.3  1.2  1.7 0.45
  Opioids, %  0.0  0.0  0.0 na
  Benzodiazepines, %  0.0  0.0  0.0 na
 Sleep characteristics3
  Pretty/very bad sleep
  quality (component 1), %
43.3 36.5 38.3 0.33
  Sleep duration < 6 h 
  (component 2), %
30.0 24.7 26.1 0.37
  Sleep efficiency < 75 % 
  (component 4), %
33.3 30.6 31.3 0.48
  Problems with daytime 
  sleepiness (component 7),%
23.3 24.1 24.4 0.55
  Sleep summary score4, median  3.5  4.0  4.0 0.67
1 Self-report of RLS symptoms in 1st degree relative
2 Reported intake of medications over the last 7 days with subsequent classification according to the Anatomical 
–Therapeutical Classification (ATC Code)
3 Assessed with 4 out of 7 components of the Pittsburgh Sleep Quality Index
4 Summary score based on the components 1, 2, 4 and 7 of the Pittsburgh Sleep Quality Index with a minimum 
score of 0 (best) and maximum score of 12 (worst)
na not analyzed
Table 3  Clinical characteristics of cases with RLS 
according to an individually known or unknown 
diagnosis of RLS
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tween individuals with a known and an unknown diag-
nosis.
■ Treatment preference for RLS
In Table 4 the proportions of RLS cases with a wish for 
treatment is shown according to gender, age, symptom 
frequency and migrational background. A significant 
higher proportion of cases with a known RLS diagnosis 
expressed a wish for treatment compared to those not 
knowing about the diagnosis. Interestingly, treatment 
wish was very similar in men and women. It increased 
with age and with more frequent symptoms. These in-
creases were stronger among cases with a known diag-
nosis. 
■ Association with treatment wish
In Table 5, potential determinants of a wish for RLS 
treatment are shown. In multivariable logistic regres-
sion analysis cases with daily symptoms were more than 
five times as likely to express a treatment wish compared 
to those with less frequent symptoms. Each additional 
point in the sleep summary score increased the chance 
for this wish by 33 %. A known history of diabetes was 
the strongest determinant of treatment wish; however, 
the confidence interval around the odds ratio was very 
wide due to very few cases. Interestingly, knowledge 
about the RLS diagnosis was a strong determinant of 
treatment wish of borderline significance, indepen-
dently of the other factors listed in the table.
We additionally analysed other social as well as clini-
cal factors for a relation with treatment wish. None of 
these other variables was a significant determinant.
Discussion
In a population-based study we found an overall preva-
lence of RLS of 8.8 % in the adult population aged 25 to 
75. About every fourth of these RLS cases knew about a 
doctor diagnosis of RLS. Thus, in contrast, 75 % of the 
cases in this community study were previously un-
known. Interestingly, every third male case knew about 
the diagnosis as compared to only every fifth female 













 Positive treatment wish % % %
 Overall 33.3 14.1 17.9 0.05
 By gender
  Women 30.0 12.5 15.2 0.17
  Men 36.4 17.2 22.5 0.19
 By age group
  ≤ 45 years 25.0  4.2  7.1 0.27
  > 45 years 35.3 18.0 21.8 0.12
 By symptom frequency
  Daily 75.0 25.0 35.5 0.12
  1–6/week 35.7 21.3 24.6 0.22
  < 1/week 20.0  5.4  7.1 0.32
 By migrational background1
  Yes  0.0 30.0 21.4 0.33
  No 41.2 12.0 17.4 0.009
1 First and second generation migrants, classified by own and parents place of birth and nationality
Table 4  Treatment wish of affected individuals 
according to an individually known or unknown 
diagnosis of RLS
Table 5  Determinants of a treatment wish for RLS in the Dortmund Health Study
All RLS cases (N = 115)
 Determinants OR* 95 % CI* p
 Age (per 10 years increase)  1.23 [0.69–2.22] 0.48
 Male gender  0.52 [0.11–2.51] 0.41
 Symptoms daily  5.35 [1.17–24.57] 0.03
 Sleep summary score1 (per point increase)  1.33 [1.04–1.69] 0.02
 History of diabetes2 19.20 [2.88–295.6] 0.004
 Positive family history3  2.94 [0.75–11.50] 0.12
 Known RLS diagnosis4  3.48 [0.91–13.30] 0.07
* Odds ratio and 95 % confidence intervals derived from logistic regression with 
treatment wish as the dependent and all determinants listed in the table being the 
independent variables
1 Summary score based on the components 1, 2, 4 and 7 of the Pittsburgh Sleep 
Quality Index and a minimum score of 0 (best) and maximum score of 12 (worst)
2 Self-reported physician diagnosis of diabetes
3 Self-report of RLS symptoms in 1st degree relative
4 Self-reported physician diagnosis of RLS
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ment with a considerably higher proportion among 
those with a known diagnosis of RLS. A generalisation 
of the treatment wish proportion and the observed over-
all prevalence to the Dortmund population within the 
age range of 25 to 75 years (n = 420,087) would yield 
6,617 individuals within the city (1.6 %) with RLS and a 
treatment wish. 
Our study is the third population-based study in Ger-
many and the fourth within German-speaking countries 
that used identical methods to classify cases. Compared 
to the other three studies [7, 8, 10] we observed a slightly 
lower overall prevalence based on the presence of the 
IRLSSG diagnostic criteria. However, the prevalence of 
9.8 % in the Augsburg study [8] and 10.6 % in the Bru-
neck study [7] was assessed in considerably older popu-
lations which are known to have higher prevalences. 
Restricting the participants of the Dortmund Health 
Study to age groups 65 and older yielded an RLS preva-
lence of 8.5 % which is still slightly lower than in the 
other two studies. We would consider these differences 
in prevalences as being low, potential explanations in-
clude regional variabilities within Germany and/or Ger-
man-speaking countries, slight differences in the pro-
portion of female participants given the considerable 
higher prevalence in women and a higher proportion of 
participants with a migrational background. The latter 
group had a lower overall prevalence than people with-
out a migrational background in our study (6.7 % vs. 
9.2 %); the difference, however, did not reach statistical 
significance. Among individuals with a migrational 
background first, second and third generation Turkish 
migrants represent the largest group in the Dortmund 
region, but many other nationalities are also represented. 
Interestingly, a recent door-to-door survey in Turkey 
yielded a lower prevalence of 3.2 % [5, 10]. The lower 
prevalence among migrants in our study was observed 
despite the process of cultural assimilation and the use 
of the same health care system and might indicate dif-
ferences in genetic predisposition. This observed differ-
ence, however, suggests that population-based studies 
should assess and stratify prevalences of RLS according 
to migrational background. Symptom frequency and 
symptom duration did not differ significantly between 
patients with previously known versus previously un-
known RLS despite a higher proportion with frequent 
symptoms among those with a known RLS diagnosis. 
Sleep characteristics, a supportive symptom in RLS, 
were considerably worse in all cases compared to non-
cases but very similar in both case groups.
We observed a stronger treatment wish among cases 
who knew about their disease status than among indi-
viduals with RLS not yet knowing about the condition. 
It is reasonable to assume that knowledge about a dis-
ease status increases the wish for treatment, irrespective 
of RLS symptoms. Since there is no absolute indication 
for the treatment of RLS one has to be aware that clas-
sifying the symptoms as a disease will induce a wish for 
treatment in an affected individual. Next to a known RLS 
diagnosis daily RLS symptoms and poor sleep could be 
identified as main determinants of treatment preference 
in RLS sufferers. People who are still at work are usually 
more sensitive to poor sleep and may ask for RLS spe-
cific treatment to improve sleep more often than older 
retired people. To our knowledge, our study is the first to 
analyze treatment wish of RLS cases in a population-
based survey. It adds to one other study that examined 
treatment preference in a patient population presenting 
to a primary care physician [6]. That survey suggested 
an RLS treatment preference about 2 %–3 %; however, 
patients were not asked directly whether they wish an 
RLS-specific treatment or not but were stratified by hav-
ing relevant RLS symptoms likely to require medical 
management. This might be the reason why the percent-
age of patients who needed RLS-specific treatment was 
about twice as high as in our study. Since treatment of 
RLS is not only known to be effective but also costly, and 
since we do not know to date whether an early dopami-
nergic treatment might worsen the long-time course of 
RLS patients [8], it is important to know exactly how 
many patients really need to be treated and what the dif-
ferent determinants of treatment are.
Our study has several strengths and limitations. It is 
based on a study sample drawn from the general popula-
tion in a defined region using established epidemiologi-
cal methods. Standardized methods to assess and clas-
sify RLS including the standard diagnostic criteria of the 
IRLSSG [1] were used, specifically trained interviewers 
performed all interviews. We were able to assess RLS 
symptom frequency and disease-related consequences 
such as sleep disturbance. The population under study 
included a broad age range, and we were able to differ-
entiate between people with and without a migrational 
background. We were not able to differ between idio-
pathic and symptomatic RLS which might influence 
treatment preference and we did not assess RLS severity 
individually. 
We conclude that RLS is common in the general pop-
ulation; however, only every fifth case would ask for 
treatment if this would improve her or his symptoms. 
This difference indicates that a treatment decision 
should be based on individual preferences and be done 
with caution. Prevalences in this study translate to an 
overall proportion of 1.6 % in the adult population in 
Dortmund with a treatment wish due to RLS. This wish 
is mainly determined by a previously known RLS diag-
nosis, daily symptoms and poor sleep. Knowledge of 
these determinants may be an important step for the in-
teraction between patient and physician in the decision 
about treatment. Every fourth case already knew a diag-
nosis of RLS indicating that RLS has given up its status 
as “the most common medical condition you have never 
heard of” (RLS foundation, US).
  1371
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